

**THIS PAGE IS INSERTED BY OIPE SCANNING
AND IS NOT PART OF THE OFFICIAL RECORD**

Best Available Images

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

BLACK BORDERS

TEXT CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT

BLURRY OR ILLEGIBLE TEXT

SKEWED/SLANTED IMAGES

COLORED PHOTOS HAVE BEEN RENDERED INTO BLACK AND WHITE

VERY DARK BLACK AND WHITE PHOTOS

UNDECIPHERABLE GRAY SCALE DOCUMENTS

**IMAGES ARE THE BEST AVAILABLE
COPY. AS RESCANNING *WILL NOT*
CORRECT IMAGES, PLEASE DO NOT
REPORT THE IMAGES TO THE
PROBLEM IMAGE BOX.**

PCT

SCIENCE IN

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :

C12N 9/08, C12Q 1/30, A61K 38/44

A1

(11) International Publication Number:

WO 98/37182

(43) International Publication Date:

27 August 1998 (27.08.98)

(21) International Application Number: PCT/CA98/00120

(22) International Filing Date: 18 February 1998 (18.02.98)

(30) Priority Data:

08/802,271

19 February 1997 (19.02.97)

US

(71) Applicant: UNIVERSITE LAVAL [CA/CA]; Cité Universitaire, Québec, Québec G1K 7P4 (CA).

(72) Inventors: LAPOINTE, Serge; 407 Route du Pont, #4, St.-Nicolas, Québec G7A 2V4 (CA). SIRARD, Marc-André; 4 Place des Mélèzes, Breakeyville, Québec G0S 1E1 (CA).

(74) Agent: COTE, France; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: OVIDUCTAL CATALASE BINDING TO THE MEMBRANES OF SPERMATOOZOA AND USES THEREOF

(57) Abstract

The present invention relates to a novel oviductal catalase having a molecular weight of about 60 KDa and which binds to a spermatozoa membrane outer surface, wherein said catalase once bound to the spermatozoa membrane outer surface protects said spermatozoa against oxidation. A method of stabilizing spermatozoa membrane and improving spermatozoa survival during migration in oviduct and/or uterus for artificial insemination; which comprises coating spermatozoa with such a catalase enzyme. The use of a catalase enzyme for improving spermatozoa survival during migration in oviduct and/or uterus in cases of female infertility due to the absence of endogenous catalase in the genital tract of the female subject; which comprises administering catalase in the female genital tract before coit or coating spermatozoa with the catalase enzyme for artificial insemination. Also provided herein are methods of diagnostic of male or female infertility.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MR	Mauritania	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

OVIDUCTAL CATALASE BINDING TO THE MEMBRANES OF
SPERMATOOZOA AND USES THEREOF

BACKGROUND OF THE INVENTION

5 (a) Field of the Invention

The invention relates to an oviductal catalase having a molecular weight of about 60 KDa and which binds to a spermatozoa membrane outer surface, uses thereof for protection and/or preservation of spermatozoa; uses thereof in artificial insemination, and a method of diagnostic of male or female infertility.

10 (b) Description of Prior Art

Artificial insemination (AI) has changed the face of the dairy industry. Faster genetics improvement of a herd by use of high quality bull semen is now possible, at reasonable cost, for any farmer. This is feasible by using cryopreservation by which a single bull can inseminate thousands of cows. However, during the cryopreservation process the sperm undergo several tremendous changes in cell volume. Such massive shrinkage and swelling leads to ultrastructural changes in the sperm membranes, increasing their permeability, ultimately resulting in enzyme leakage and the accumulation of intracellular calcium. Even with the best preservation techniques to date, post-thaw survival is restricted to about 50% of the sperm population. Moreover, most surviving spermatozoa have characteristics which distinguish them from spermatozoa before cryopreservation. As a consequence, the functions of cryopreserved sperm are limited, as expressed by their reduced motility, viability and fertility in vivo, which can be only partially compensated by inseminating greater numbers of live spermatozoa. In fact, to obtain a normal fertility rate, the insemination must be performed with a minimum of 6×10^6 motile sperm per

straw after thawing ($\sim 12 \times 10^6$ total), compared to only 2.5×10^6 motile fresh sperm.

Sperm quality is strongly related to free radical action and the protection provided by endogenous antioxidants. Over time, the loss of sperm motility in the rabbit and human is correlated with spontaneous lipid peroxidation (Alvarez JG et al., 1987, *J. Androl.*, 8:338-348). It has also been reported that superoxide dismutase activity (SOD) activity is a good predictor of the lifetime of a human sperm sample (Alvarez JG et al., 1987, *J. Androl.*, 8:338-348), and that total cellular SOD can be conveniently measured by sperm surface SOD activity. Indeed, a growing body of evidence indicates that a significant factor in human male infertility involves a loss of sperm function as a consequence of oxidative stress (Aitken RJ, 1994, *Reprod. Fertil. Dev.*, 6:19-24). Furthermore, fresh bull semen of lower quality (<70% motile sperm) has lower antioxidant activity than in normal semen. However, the byproduct of SOD action is the production of hydrogen peroxide (H_2O_2). Hydrogen peroxide is a highly reactive oxygen species which is one of the most toxic compound to sperm. H_2O_2 could be a major player in the death of sperm in the female genital tract.

It would be highly desirable to be provided with a catalase which binds to a spermatozoa membrane outer surface to protect the spermatozoa against oxidation by H_2O_2 .

SUMMARY OF THE INVENTION

One aim of the present invention is to show that oviductal catalase reverses the decreased motility of bovine sperm in culture medium containing specific amino acids (AA). Since those AA are found in the bovine uterus as well than the oviduct, H_2O_2 could be a

major player in the death of sperm in the female genital tract. Catalase catalyze the decomposition of H_2O_2 in water and oxygen, thus breaking the chain reaction of free radical production (Aitken RJ, 1995, *Reprod. Fertil. Dev.*, 7:659-668). Reactive oxygen species, such as H_2O_2 , lead to lipid peroxidation, and that process could be the limiting factor of the lifetime of mammalian spermatozoa in the oviduct (Alvarez JG et al., 1987, *J. Androl.*, 8:338-348). Although components of oviductal fluid, or supernatants of in vitro oviductal culture promote sperm survival, in humans, horses, and cattle, the mechanism by which the oviduct maintain sperm viability is not known.

We report here a catalase activity in the bovine oviductal fluid which varies during the estrous cycle. Immunoaffinity column against human erythrocytes catalase, or direct addition of the antibody, did remove all catalase activities from the oviductal fluid. Indirect immunostaining of spermatozoa incubated in the oviductal fluid revealed an intense brown staining on the acrosomal cap. Since H_2O_2 is a key product in the chain reaction of free radical production which leads to lipid peroxidation, this new catalase enzyme of the present invention may be the foremost important product of the female tract for sperm survival.

In accordance with the present invention there is provided an oviductal catalase having a molecular weight of about 60 KDa and which binds to a spermatozoa membrane outer surface, wherein the catalase once bound to the spermatozoa membrane outer surface protects the spermatozoa against oxidation. A preferred oviductal catalase in accordance with the present invention is encoded by the DNA sequence set forth in SEQ ID NO:1 and has the amino acid sequence set forth in SEQ ID NO:2.

In accordance with the present invention there is provided a method of stabilizing spermatozoa membrane and improving spermatozoa survival during migration in oviduct and/or uterus for artificial insemination; which comprises coating spermatozoa with a catalase enzyme.

In accordance with the present invention, the catalase enzyme may be isolated from a biological source or is recombinantly produced. The catalase enzyme may be isolated from oviduct (Fallopian tubes) and cervical mucus of human, bovine, caprine, equine, ovine or porcine origin.

In accordance with the present invention, the spermatozoa may be of bovine, caprine, equine, ovine, porcine, canine, feline, primate, pachyderm or human origin.

In accordance with the present invention there is provided a composition of spermatozoa for artificial insemination with stabilized spermatozoa membrane and improved spermatozoa survival during migration in oviduct and/or uterus, which comprises spermatozoa coated with a catalase enzyme with or without an agent preventing lipid peroxidation.

The coated spermatozoa of the composition may be frozen.

The agent preventing lipid peroxidation of the composition may be selected from the group consisting of Vitamin E (α -tocopherol), Vitamin C (ascorbic acid), pyruvate, glutathion, uric acid, taurine, albumine, DMSO, superoxid dismutase (SOD), catalase (from many sources) and lactoferrin.

In accordance with the present invention there is provided a method of diagnostic of low fertility or infertility in a male subject; which comprises the steps of:

a) incubating spermatozoa obtained from the male subject with a catalase enzyme or with biological fluid containing a catalase enzyme; and

5 b) determining the presence of catalase on spermatozoa membrane; whereby the incapacity of spermatozoa to bind to catalase is indicative of infertility of the subject.

10 In accordance with the present invention there is provided a method of diagnostic of low fertility or infertility in a female subject; which comprises the step of determining the absence or presence of an oviductal catalase in oviductal fluid and/or cervical mucus obtained from the subject; whereby the absence of catalase is indicative of infertility of the subject.

15 In accordance with the present invention, the determination of the presence of catalase may be effected using an anti-catalase antibody directly or indirectly detected.

20 In accordance with the present invention there is provided the use of a catalase enzyme for improving spermatozoa survival during migration in oviduct and/or uterus in cases of female infertility due to the absence of endogenous catalase in the genital tract of the female subject; which comprises administering catalase in the female genital tract before coït or coating
25 spermatozoa with a catalase enzyme for artificial insemination.

BRIEF DESCRIPTION OF THE DRAWINGS

30 Fig. 1 is a graph of sperm motility measurements following preincubation with bovine oviductal fluid (OF);

Fig. 2 is a graph of assay of the catalase activity found in the bovine oviductal fluid; and

Fig. 3 illustrates the immunodetection of oviductal fluid catalase (OFC) in bovine, porcine and human oviductal fluid;

Figs 4A to 4D illustrate the binding of OFC to bovine sperm; and

Fig. 5 illustrates the binding of bovine ^{125}I -OFC to bovine and porcine sperm membranes.

DETAILED DESCRIPTION OF THE INVENTION

Hydrogen peroxide (H_2O_2) is a highly reactive oxygen species which is one of the most toxic compound to sperm. H_2O_2 not only inhibit the livability, but also the acrosome reaction, the sperm binding with the egg and oocyte penetration. The oviductal catalase of the present invention activates the decomposition of H_2O_2 in water and oxygen, thus breaking the chain reaction of free radical production leading to lipid peroxidation. The catalase activity in oviductal fluid increased during the cycle, to reach its maximal activity just before ovulation (days 18-20). No significant difference in the activity was seen between the fluid from isthmus or ampulla. Immunoaffinity column against bovine liver catalase, or direct addition of the antibody, did remove all catalase activities from the oviductal fluid. Purification of the oviductal fluid catalase was achieve by its elution from the immunoaffinity column. Indirect immunostaining of spermatozoa incubated in the oviductal fluid revealed a intense brown staining on the acrosomal cap.

Since H_2O_2 is a key product in the chain reaction of free radical production, this new enzyme could be the foremost important product of the female tract for sperm survival. Because this enzyme binds to spermatozoa, it could be use to protect the sperm cells when they are thaw up until they are used to fertilize.

Collection and Preparation of Oviductal Fluid

Oviducts from estrous, metestrous and proestrous cows (four of each) were transported from the slaughterhouse to the laboratory on ice, and dissected free from other tissues. Depending of the experiment, the isthmus was separated from the ampulla. Oviductal cells were extracted by compressing the oviducts with a glass slide and the mucosal tissue was rinsed in Tris-EDTA (40 mM, 1 mM) buffer. The cells were incubated twice for 30 min at 37°C then centrifuged (10 min, 1500 x g) and the supernatant reserved each time. The pooled supernatant (containing oviductal secretions only) was then centrifuged (15 min, 20 000 x g) filtered (0.45 µm) and frozen for further experimentation. Four different pools were constituted.

Sperm Motility analyses following incubation with oviductal fluid

Frozen semen, pooled from five bulls, was prepared and donated by the Centre d'Insémination Artificielle du Québec Inc. (C.I.A.Q. Inc., St-Hyacinthe, Québec, Canada). The same pool was used throughout the study. Straws were thawed in a water bath (35°C for 60 sec) and the sperm were washed twice in Sp-Talp (Parrish JJ et al., 1988, *Biol. Reprod.*, 38:1171-1180) containing 6 mg/ml BSA. Approximately 15 million spermatozoa (50 µl) were added to a pre-equilibrated solution composed of 225 µl Tris-EDTA containing 0.5 mg/ml OFP plus 225 µl TCM-PVP (TCM-199 + 3 mg/ml Polyvinylpyrrolidone-360™ (PVP), Sigma) or control solution (225 µl Tris-EDTA containing 0.5 mg/ml PVP + 225 µl TCM-199-PVP) for a final concentration of about 30 million sperm/ml. Tubes were mixed and incubated for 30 min (37°C, 5% CO₂) in a humidified incubator. Following this, tubes were centrifuged 5 min at 250 x g, the supernatant removed and the pellet washed once more

with 500 μ l of TCM-PVP. The final pellet was dissolved in 500 μ l TCM-PVP and the motility recorded as time 0. Sperm motility was then measured every 2 h for up to 6 h.

5 Sperm motility (i.e. percentage of motile sperm) was assessed with a Hamilton-Thorne Sperm Motility Analyzer™ (Hamilton-Thorne Research, Beverly, MA). For each tube, 2 thoroughly mixed aliquots (5 μ l each) of sperm suspension were placed on a prewarmed MicroCell™
10 counting chamber (Conception Technologies, San Diego, CA). The chamber was then placed on the warmed stage (37.5°C) of the motility analyzer and a minimum of 8 fields and 150 sperm were selected and scanned automatically by the analyzer for evaluation of motility.
15 Slow cells (track speed (VCL) less than 20 μ m/sec) were counted as immotile. Three independent binding-motility experiments were performed, with the same oviductal fluid batch.

20 Determination of the catalase activity in the oviductal fluid

Catalase activity in the oviductal fluid was assayed by the disappearance of H_2O_2 with a spectrophotometer. Briefly, 30% H_2O_2 (Sigma Chemical Company,
25 St-Louis, MO) was dilute in 50 mM phosphate buffer until the absorbency at 240 nm ranged from 0.550 to 0.520. Fifty μ l of oviductal fluid was then add to 950 μ l of that solution, vortexed and the optical density was recorded at 15 sec and 1 min later. Dilution
30 of oviductal fluid was performed as necessary to obtain similar decrease in optical density from one sample to and other. Knowing the protein concentration of each sample (Biorad) and that a 0.050 decrease at 240 nm correspond to the disappearance of 3.45 μ moles, total
35 units of catalase activity per mg of protein in oviduc-

tal fluid was calculated. Each sample was assayed twice.

Purification of the catalase activity

5 Since a catalase activity was detected in oviductal fluid, a immunoaffinity column was prepared to purify this activity. Two mg of a purified IgG fraction from rabbit serum, directed against a catalase (from bovine liver; Biomol Research Laboratories Inc. 10 Plymouth meeting, CA), was coupled to 3 ml of cyanogen bromide-activated sepharose beads (Pharmacia Biotech, Baie d'Urfé, Québec, Canada). Hundred fifty (150) ml of oviductal fluid were loaded onto the anti-catalase column and the beads were washed with 30 ml of PBS. 15 Fractions of 1 ml were collected and the catalase activity in each tube was assay as previously describe. To elute the catalase activity from the column, 10 ml of 0.1M glycine, pH 2.6, was loaded on the column. 20 Fractions of 900 μ l were collected and 100 μ l of Na_2HPO_4 0.5 M, pH 11.5 was added to the tube to neutralize the collected fraction. Catalase activity in each of the ten fractions was assay as describe previously.

25 Direct effect of the addition of an anti-catalase on the catalase activity in the oviductal fluid was also measured. Anti-catalase IgG was diluted at various concentration in oviductal fluid, and incubated for 90 min at 37°C. The residual catalase activity in the fluid was then assayed as described previously.

30 Immunodetection of Oviductal Fluid Catalase (OFC)

Proteins from bovine, porcine and human oviductal fluid, or human cervical mucus was precipitated using the methanol-chloroform method. Briefly, 400 μ l 35 of MeOH was added to 100 μ l of proteins solution and vortexed. After that, 100 μ l of CHCl_3 were added and

vortexed. Then 300 μ l of H₂O were added, vortexed, and the tubes were centrifuged 2 min. at 10 000 x g. The upper aqueous phase was removed and discarded. Three hundred μ l of MeOH were added to the remaining, vortexed and centrifuged 5 min. at 10 000 x g. Tubes were decanted and air dry. Pellets were dissolved and boiled in SDS-blue buffer. Fractions were submit to one-dimensional SDS-PAGE electrophoresis. Electrophoretic patterns were stained with bromophenol blue or transfer on a nitrocellulose membrane.

Western blots were saturated overnight at 4°C in PBS containing 5% (w/v) defatted milk. After three washes with 0.2% Tween 20 in PBS, the electrotransfers were incubated for 2 hrs with the anti-catalase (from bovine liver; Biomol) diluted 1:3000 in PBS. Before use, the antiserum was preadsorbed on a human keratin powder. After three washes with PBS-0.2% TWEEN™ 20, the nitrocellulose membrane were incubated at room temperature for 45 min with a peroxidase-conjugated anti-rabbit IgG diluted 1:3000 in PBS and washed three times with PBS-0.2% TWEEN™ 20. The immune complexes were detected using a BIOMAX™ film (Eastman Kodak, Rochester, NY) after incubation with a chemiluminescent substrate of peroxidase as recommended by the supplier's instruction (ECL™ kit: Amersham, Buckinghamshire, UK).

Immunostaining of oviductal fluid catalase bound to bovine spermatozoa

Frozen semen from the same pool was thawed as before and the sperm were washed twice in PBS buffer (0.02% KCl, 0.02% KH₂PO₄, 0.11% Na₂HPO₄, 0.01% CaCl₂, 0.01% MgCl₂, 0.8% NaCl, 0.1% BSA) containing 6 mg/ml BSA (Fraction V, Sigma Chemicals, St-Louis, MO). Ten μ l of freshly washed sperm (150 million/ml) were added to 45 μ l of oviductal fluid, and 45 μ l of TBS buffer (10 mM Tris, 150 mM NaCl) with 3.5 mM CaCl₂, for

a final calcium concentration of 1.5 mM. The preparation (final volume = 100 μ l) was then mixed and incubated for 30 min at 38.5°C. Following incubation, tubes were centrifuged 10 min at 400 x g, the supernatant removed and the pellet washed 3 more times with 0.5 ml of PBS. Spermatozoa were smeared onto microscope slides and air dried.

Determination of catalase presence at sperm surface was done by indirect immunostaining. Antigen localization was performed by the avidin-biotin peroxidase staining procedure using the Vectastain ABC™ kit (Vector Labs, Burlingame, CA). Nonspecific staining was avoided by a 1-h preincubation of the spermatozoa fixed slides with 10% (v:v) goat serum in PBS (pH 7.4) followed by three washes in PBS. Slides were incubated for 2 h with a rabbit (IgG fraction) anti-catalase from bovine liver (Biomol). The antibody was used at a dilution of 1/1000 in PBS. After three washes with PBS, slides were treated for 30 min with goat biotinylated anti-rabbit IgG (Sigma) diluted 1/100 in PBS, washed three times in PBS, and then incubated for 30 min with Vectastain ABC™ reagent. After three washes in PBS, spermatozoa were revealed with peroxidase substrate (0.118 M aminoethyl carbazol (Sigma) in 100 mM sodium acetate buffer, pH 5.2) in the presence of 0.002% H₂O₂ for exactly 10 min. Slides were washed in water and counterstained with Harris hematoxylin (Sigma, ACCUSTAIN™), fixed with a 5% acetic acid solution, washed extensively in water, and finally mounted with DAKO GLYCERGEL™ (Dako Corp., Carpinteria, CA) under coverslip. Great care was taken in order to proceed all samples the same manner. They were all treated in parallel in order to avoid technical variability and to allow comparison of staining from one sperm sample to the other.

Radio-Iodination of the purified Oviductal Fluid Catalase (OFC)

Purified oviductal fluid catalase from immunoaffinity column was labeled with ^{125}I . Briefly, 10 μl of Chloramine-T (0.05 mg/ml PBS) was added to 10 μl of iodination buffer (0.3 M NaPO_4 pH 7.5; IB) 10 μl OFC (0.5 mg/ml IB) and 10 μl of $\text{NaI-}^{125}\text{I}$ (1 mCi in IB) for 5 min. The reaction was stopped by adding 1 ml of PBS. The sample was then eluted with PBS+0.1% BSA on a 25 ml³ SEPHADEXTM G-75 fine column to remove labeled OFC from free ^{125}I . Radioactive fractions were pooled and frozen until use.

Binding of ^{125}I -OFC to Sperm Membranes

Frozen semen, pooled from five bulls, fresh pig semen, or uterine mouse cell (as negative control) were washed twice in PBS buffer (0.02% KCl , 0.02% KH_2PO_4 , 0.11% Na_2HPO_4 , 0.03% CaCl_2 , 0.01% MgCl_2 , 0.8% NaCl , 0.1% BSA). Twenty μl of the cell suspension (200 million/ml) were added to 20 μl of the labeled OFC (~600 000 cpm), and 70 μl of PBS buffer. The preparation was then mixed and incubated for 30 min at 37°C. Following incubation, tubes were centrifuged 10 min at 400 x g, the supernatant removed and the pellet washed 3 more times with 1 ml of PBS, changing the tube each wash. The final pellet of cells was dissolved and boiled in 110 μl of SDS-blue buffer and 10 μl was counted with a gamma counter (LKB 1261 Multigamma, Pharmacia-LKB, Baie d'Urfé, Qc, Canada). The remaining volume was submitted to gel electrophoresis (see below).

One-Dimensional Gel Electrophoresis and Autoradiography

Solubilized sperm, precipitated labeled OFP were separated using one-dimensional SDS-PAGE and a continuous buffer. Resolving gels were cast using 12% acrylamide; stacking gels contained 4% acrylamide. Polymerization of gels was induced by addition of 5% ammonium

persulfate. A measured volume of labeled OFP bound to sperm samples (1000-2000 cpm) were loaded on gels. Molecular weight ^{14}C -methylated protein standards were lysozyme, 14.3 kDa; carbonic anhydrase, 30 kDa; egg albumin, 46 kDa; bovine serum albumin (BSA), 66 kDa; phosphorylase-b, 97.4 kDa; and myosin, 220 kDa (Amersham, Oakville, ON.)

After electrophoresis, gels were dried at 80°C in a slab gel dryer (Biorad, Model 543, Mississauga, ON) between two sheets of porous membrane. Dried gels were placed in a KODAK™ X-ray exposure holder with KODAK X-OMAT™ XAR-5 film and an intensifying screen, and stored at -80°C for 5-10 days. Films were processed with a KODAK X-OMAT™ automatic developer.

Effect of the binding of OFP on the maintenance of sperm motility

Fig. 1 represent a graph of sperm motility measurements following preincubation with oviductal fluid (OF). Freshly washed sperm were preincubated in the presence or absence of OF, washed then incubated for 6 h in TCM-199. The motility was then recorded with a Hamilton-Thorne motility analyzer. Results are means (\pm SEM) of 3 independent experiments (** $P < 0.01$; Fig. 1).

Since only some proteins from OF bind to sperm membranes, this experiment was performed to investigate whether this binding affects the maintenance of sperm motility. This figure shows that after a short 30 min incubation in presence of calcium and one wash, survival was better in presence of oviductal fluid (time 0). This difference is not significant compare to control for the first 4 h ($P > 0.5$), but this trend was maintained through 6 h, at which time the percentage of motile sperm incubated in control media dropped dramatically ($23.8\% \pm 5.7$) whereas that of sperm incubated

with OF remained at a higher level ($44.2\% \pm 6.3$, $P < 0.01$). These data suggest a possible association between binding of specific proteins to sperm and the subsequent prolongation of sperm viability.

5

Catalase activity in the oviduct

In culture medium containing specific amino acids, high H_2O_2 concentration are present. Since this negative effect could be eliminated by *in vitro* oviduc-
10 tal secretions, or only by a preincubation of sperm in oviductal fluid (Fig. 1), we suspected a catalase activity in bovine oviductal fluid.

The presence of a catalase activity in that fluid is shown in Fig. 2. Tubal cells were harvested
15 and washed to obtain the fluid. Determination of the catalase activity was measured twice by the disappearance of H_2O_2 at 240 nm with a spectrophotometer. Results are means (\pm SEM) of 4 independent experiments (* $P < 0.05$ from days 0-3; Fig. 2).

20

Catalase specific activity increased in the fluid during the estrous cycle, to reach maximal activity just before ovulation (days 18-20). Fluid from pre-ovulatory oviduct showed large variations in the catalase specific activity. In two experiments the
25 level were as low a fluid from day 0-3, while in two others experiments the catalase specific activity was twice superior. Although the catalase activity in the ampulla was always above than the isthmus, this difference was not significant ($P = 0.081$).

30

Neutralization of the catalase activity

To further prove the presence of a catalase activity in the bovine oviductal fluid, a purified IgG fraction from rabbit serum, directed against a catalase
35 from bovine liver, was used to neutralize the oviductal catalase activity. A immunoaffinity column coupled

with the anti-catalase removed 100% of the original catalase activity found in the fluid. Direct addition of the antibody in the oviductal fluid also removed the activity in a dose dependent-manner, as seen in Table 1.

Table 1

Effect of the addition of an anti-catalase on the catalase activity in the oviductal fluid

Antibody added	Residual catalase activity
None	100%
1/1000	31%
1/500	22%
1/300	14%
1/200	9%
1/100	6%

Purified IgG fraction from rabbit serum, directed against a catalase from bovine liver, was diluted at various concentration, and incubated for 90 min at 37°C. The residual catalase activity in the oviductal fluid was then assayed as described above.

Purification of the catalase activity

Immunoaffinity purification of the oviductal catalase activity was successful. Fractions eluted from the column were highly active, while no activity remained in the oviductal fluid passed through the column. The purify fraction showed a single band in the 60 kDa area on SDS page electrophoresis (bromophenol blue coloration).

Immunodetection of Oviductal Fluid Catalase

As seen in Fig. 3, two major bands at 60 and 40 kDa, were detected by Western blot in bovine oviductal fluid (open arrow head; lane 1). The 60 kDa band does not appear in lane 2 representing oviductal fluid,

passed through the immunoaffinity column, without catalase activity. Lanes 3 and 4, represent respectively 10 and 100 μ l of the purified catalase fraction eluted from the immunoaffinity column. The presence of the 60 kDa band can also be seen in porcine oviductal fluid (lane 5), human oviductal fluid (lane 6) and human cervical mucus (lane 7), and correlate with the catalase activity also found in these three fractions.

10 Immunostaining of oviductal fluid catalase bound to bovine spermatozoa

The results presented in Fig. 1 suggested a possible association between binding of specific proteins to sperm and the subsequent prolongation of sperm viability. To verify that this effect could be due to the binding of a catalase from the oviductal fluid, an immunoperoxidase staining of the spermatozoa incubated with the fluid, probed with the anti-catalase was performed.

20 Spermatozoa incubated in the oviductal showed an intense brown staining of the acrosomal cap as illustrated by arrow heads in Fig. 4A (400 x) and Fig 4B (200 x). Spermatozoa incubated with catalase from bovine liver (Fig. 4C; 200 x) or in PBS alone (Fig. 4D; 25 200 x) did not show any staining, and their acrosome remained blue. Those results clearly show a specific binding of the catalase from the oviductal fluid with the spermatozoa while no such binding occurs when catalase from other sources was used.

30 Binding of 125 I-OFC to Sperm Membranes

Figure 5 shows the specific binding of 125 I-OFC to bovine and porcine sperm. As seen in Lane 1, only one major band is visible in the 60 kDa area, showing a high degree of purity of the fractions eluted from the immunoaffinity column. Bovine and porcine spermatozoa incubated in presence of the labeled OFC did bind the

protein to their surface. However, mouse uterine cells (used as a negative control) did not bind the protein which demonstrate a specific binding of the OFC only to sperm surface.

5

Discussion

Only a few studies have demonstrated the binding of oviductal proteins to the sperm of mammalian species, including human, ram, stallion, and bull. As reproduce in Fig. 1, we have previously reported that the binding of oviductal fluid proteins to the sperm membrane had a positive effect on sperm survival in TCM-199 medium. However at that time, the exact mechanism of action of those proteins was not completely understood. The current results clarify the situation and shows for the first time a potential function of the bound proteins.

Catalase has been purified from plants, bacteria, fungi, and mammalian liver and blood. Catalases from these sources show a high degree of similarity. They have a relative molecular weight in the range of 225,000 to 270,000, contain four equally sized subunits, with each possessing a ferric heme. We report here, for the first time, the presence of a catalase secreted by the mammalian oviduct. Specific catalase activity was found to increase in the oviductal fluid to the approach of the ovulation and no significant difference was found between the isthmus and the ampulla (Fig. 2). The presence of such an enzyme in the female genital tract is an outstanding discovery since H_2O_2 is highly toxic for bovine sperm. H_2O_2 not only inhibit the motility, but also the acrosome reaction, the sperm binding with the egg and oocyte penetration. Furthermore, the decomposition of H_2O_2 breaks the chain reaction of free radical production which leads to lipid peroxidation. It has been calculated

that this process could be the limiting factor of the lifetime of mammalian spermatozoa in the oviduct (Alvarez JG et al., 1987, *J. Androl.*, 8:338-348). It is therefore tempting to speculate that this new enzyme
5 is the foremost important product of the female tract for sperm survival.

Binding of spermatozoa to oviductal cells has been demonstrated in many species. This binding appears to be important as for the survival than for
10 the capacitation of the spermatozoa. During that process, spermatozoa acquire at their surface material produced by the oviductal cells. Here, we showed that the catalase secreted by the oviduct also binds the membrane of the spermatozoa. It's the first time it is
15 been shown that such an enzyme interacts so closely with mammalian sperm. *In vivo* studies showed that, before ovulation, spermatozoa interact with oviductal cells by their rostral surface, and that oviductal surface-coating material is distributed predominantly over
20 the anterior portion of the sperm head. These observations are in agreement with our results, and support the role of the oviduct as a sperm storage site since elimination of H_2O_2 from sperm environment can only have beneficial effect. The coating of sperm with an
25 oviductal catalase thus offers a maximal protection. A different method also showed that specific binding of the oviductal fluid catalase occur to bovine and also porcine sperm (Fig. 5).

In summary, we report for the first time the
30 presence of a catalase in the bovine oviductal fluid. Specific activity of this enzyme increased at the near the ovulation. Furthermore, oviductal catalase, which can be purify by immunoaffinity, appears to bind on the acrosomal cap of the spermatozoa. Since H_2O_2 is a key
35 product in the chain reaction of free radical production which led to lipid peroxidation, this new enzyme

could be the foremost important product of the female tract for sperm survival.

The enzyme complete characterization is presently in process. These will include: determination of native molecular weight and pI, partial amino acid sequence (chemical procedures) and complete sequence via cloning of the gene.

10 Different uses of the oviductal catalase of the present invention

Addition of that enzyme could greatly improve fertility rates with low sperm concentration in artificial insemination. Hydrogen peroxide (H_2O_2) is a highly reactive oxygen species which is one of the most toxic compound to sperm. In the uterine cavity, a lot of leukocytes are found at estrous time, and those cells produce large quantities of H_2O_2 . Moreover, our laboratory has recently shown that specific amino acids (AA) stimulated the production of hydrogen peroxide by dead spermatozoa. Since those AA are found in the bovine uterus as well than the oviduct, H_2O_2 could be a major player in the death of sperm in the female genital tract. In fact, Alvarez et al. calculated that lipid peroxidation (due to the presence of free radicals) is the limiting factor for the lifetime of mammalian spermatozoa in the oviduct (Alvarez JG et al., 1987, *J. Androl.*, 8:338-348). Spermatozoa coated with catalase could therefore be much more resistant to H_2O_2 found in the uterus, site where semen is deposited during AI procedure. Moreover, this catalase could not only protect sperm that are alive after thawing, but, by coating the sperm, stabilize the membrane and improve survival during migration in the uterus.

If more sperm can make it to the oviduct, the number of sperm present in one straw could be seriously reduced. This option would allow to make more straws

with the same ejaculate and therefore increase the sales for a bull in high demand. An other option is a "long range semen". Addition of the catalase to the semen could increase the insemination window from 1 day
5 to 2 days.

Relation between the binding of oviductal catalase and fertility has not been investigated yet. It is possible that, as in the capacity of the spermatozoa to bind with the oviductal cells, there are differences
10 between bulls. In which case, the binding of the catalase with the sperm could be a screening test helpful in the insemination industry. Semen from potential low fertility bulls could be screened from the start, and correction could be applied in the extender. Measure-
15 ment could be made by the flow cytometer using labeled antibody against catalase following a short preincubation in medium containing the oviductal catalase.

The bovine AI industry may not be the only one to take advantage of that discovery since a similar
20 product has been detected in oviductal fluid of the sow (Fig. 3). Boar semen is extremely affected by the freeze-thaw procedure because sperm membranes are a lot more sensitive than bull. As proposed previously, spermatozoa coated with such catalase, could have their
25 membrane stabilized and exhibit higher survival rates during normal conservation at 16°C or during freeze-thaw procedure.

This catalase could also be advantageous to detect and/or solve some human infertility problems.
30 As proposed for bulls, it is possible that there is an incapacity for spermatozoa from infertile man to bind the catalase. In such case, a screening test could be performed to avoid clinical procedures that cannot overcome the inability of the spermatozoa to survive in
35 the female tract. Addition of purified catalase to semen of patient with very low sperm count, during the

- 21 -

swim-up procedure, could increase fertility by preserving the viability of those precious spermatozoa. It is also possible that in some case, that the catalase is not produced by the female genital tract. In such circumstance, pre-treatment of the semen in vitro with purified catalase before insemination, or insertion of a capsule of catalase in the vagina of the women, before the sexual relation, could correct that infertility problem.

Those applications are only some of the possibilities with such a product.

The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.

EXAMPLE I

Detection of low fertility or fertility on male subject

Semen from any species is manipulated as described in section: Immunostaining of oviductal fluid catalase bound to bovine spermatozoa. Detection of a intense brown staining on the acrosomal cap (see Figs. 4A, 4B) signify a normal and fertile subject. However, the absence of a brown coloration on spermatozoa surfaces (such as Fig. 4D) suggest an inability for spermatozoa to bind the OFC, caused by the absence of a binding site, and a infertility problem. With the use of a specific antibody directed against the OFC binding site it will be possible to detect directly the presence of the binding site by using the same principle as in the methods described in the sections: Immunodetection of Oviductal Fluid Catalase (OFC) and Immunostaining of oviductal fluid catalase bound to bovine spermatozoa.

EXAMPLE II

Detection of the presence of catalase in female cervical mucus

Cervical mucus is collected by gynecologist. Equal volume of PBS buffer is mixed to the mucus, incubated for 30 min. at 37°C and centrifuged 10 min. at 10 000 x g. Catalase activity in the supernatant is then measure directly by spectrophotometry, or indirectly by immunodetection. Detailed description of the method to measurement of the catalase activity and presence is mentioned below (Determination of catalase activity in oviductal fluid; Immunodetection of Oviductal Fluid Catalase (OFC)).

EXAMPLE III

Methods for improving spermatozoa survival

A) In semen extenders

The purified catalase of the present invention (OFC) is added to the semen extenders destined to cryopreservation or fresh semen conservation before sperm addition. Protective effects starts immediately by removing toxic H_2O_2 from the solution and continue in the presence of spermatozoa. For semen destined to cryopreservation, allow 30-60 min. at room temperature before freezing to permit to the OFC to interact and bind to the spermatozoa membranes.

B) For spermatozoa destined to artificial insemination

Purify OFC is added to the swim-up buffer and/or the washing buffer before sperm addition. Protective effects starts immediately by removing toxic H_2O_2 from the solution and continue in the presence of spermatozoa. Purify OFC is also present in the resuspending medium to be use for artificial insemination.

- 23 -

C) Insertion of a capsule containing OFC in the vagina before coït

Purify OFC can be inserted in porous capsules membranes such as poly-lysine or collagen. The capsule
5 is then inserted in the women vagina 30-60 min. before coït. Semen deposited later on, will interact with the liberated OFC and spermatozoa will benefit from the presence of OFC to their surface.

While the invention has been described in con-
10 nection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and
15 including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended
20 claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Université Laval
- (ii) TITLE OF THE INVENTION: OVIDUCTAL CATALASE BINDING
TO THE MEMBRANES OF SPERMATOOZOA AND USES THEREOF
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: SWABEY OGILVY RENAULT
 - (B) STREET: 1981 McGill College Avenue - Suite 1600
 - (C) CITY: Montréal
 - (D) STATE: QC
 - (E) COUNTRY: Canada
 - (F) ZIP: H3A 2Y3
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/802,271
 - (B) FILING DATE: 19-FEB-1997
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Côté, France
 - (B) REGISTRATION NUMBER: 4166
 - (C) REFERENCE/DOCKET NUMBER: 6013-40PCT FC/ld
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 514 845-7126
 - (B) TELEFAX: 514 288-8389
 - (C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2282 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:

- 25 -

- (A) NAME/KEY: Coding Sequence
 (B) LOCATION: 43...1623
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

CCCCGGGCCCA CCTGCAAAGT TCTGCATCGC CACTCAGACA TC ATG GCG GAC AAC      54
                               Met Ala Asp Asn
                               1

CGG GAT CCA GCC AGC GAC CAG ATG AAA CAC TGG AAG GAG CAG AGG GCC      102
Arg Asp Pro Ala Ser Asp Gln Met Lys His Trp Lys Glu Gln Arg Ala
  5                               10                               15                               20

GCG CAG AAA CCT GAT GTC CTG ACC ACT GGA GGT GGT AAT CCA GTA GGA      150
Ala Gln Lys Pro Asp Val Leu Thr Thr Gly Gly Gly Asn Pro Val Gly
                               25                               30                               35

GAC AAA CTC AAT AGT CTG ACG GTA GGG CCC CGA GGG CCC CTT CTC GTC      198
Asp Lys Leu Asn Ser Leu Thr Val Gly Pro Arg Gly Pro Leu Leu Val
                               40                               45                               50

CAG GAT GTG GTT TTC ACT GAT GAA ATG GCT CAC TTT GAC CGG GAG AGA      246
Gln Asp Val Val Phe Thr Asp Glu Met Ala His Phe Asp Arg Glu Arg
                               55                               60                               65

ATT CCT GAG AGA GTC GTG CAT GCC AAA GGA GCA GGG GCT TTT GGC TAC      294
Ile Pro Glu Arg Val Val His Ala Lys Gly Ala Gly Ala Phe Gly Tyr
                               70                               75                               80

TTT GAG GTC ACA CAT GAC ATT ACC AGA TAC TCC AAG GCG AAG GTG TTT      342
Phe Glu Val Thr His Asp Ile Thr Arg Tyr Ser Lys Ala Lys Val Phe
  85                               90                               95                               100

GAG CAT ATT GGA AAG AGG ACG CCC ATT GCA GTT CGC TTC TCC ACT GTT      390
Glu His Ile Gly Lys Arg Thr Pro Ile Ala Val Arg Phe Ser Thr Val
                               105                               110                               115

GCT GGA GAA TCG GGC TCA GCT GAC ACA GTT CGT GAC CCT CGT GGC TTT      438
Ala Gly Glu Ser Gly Ser Ala Asp Thr Val Arg Asp Pro Arg Gly Phe
                               120                               125                               130

GCA GTG AAA TTT TAC ACA GAA GAT GGT AAT TGG GAT CTT GTT GGA AAT      486
Ala Val Lys Phe Tyr Thr Glu Asp Gly Asn Trp Asp Leu Val Gly Asn
                               135                               140                               145

AAT ACT CCC ATT TTC TTC ATC AGG GAT GCT CTA TTG TTT CCA TCC TTT      534
Asn Thr Pro Ile Phe Phe Ile Arg Asp Ala Leu Leu Phe Pro Ser Phe
                               150                               155                               160

ATC CAC AGC CAG AAG AGA AAC CCT CAA ACG CAC CTG AAG GAT CCG GAC      582
Ile His Ser Gln Lys Arg Asn Pro Gln Thr His Leu Lys Asp Pro Asp
  165                               170                               175                               180

ATG GTC TGG GAC TTC TGG AGC CTG CGT CCT GAG TCT CTG CAT CAG GTT      630
Met Val Trp Asp Phe Trp Ser Leu Arg Pro Glu Ser Leu His Gln Val
                               185                               190                               195

```

TCC	TTC	CTG	TTC	AGT	GAT	CGA	GGG	ATT	CCA	GAT	GGA	CAC	AGG	CAC	ATG	678
Ser	Phe	Leu	Phe	Ser	Asp	Arg	Gly	Ile	Pro	Asp	Gly	His	Arg	His	Met	
			200					205					210			
AAT	GGA	TAT	GGA	TCG	CAT	ACT	TTC	AAG	CTG	GTT	AAT	GCA	AAT	GGA	GAG	726
Asn	Gly	Tyr	Gly	Ser	His	Thr	Phe	Lys	Leu	Val	Asn	Ala	Asn	Gly	Glu	
		215					220					225				
GCA	GTT	TAT	TGC	AAA	TTC	CAT	TAT	AAG	ACT	GAT	CAG	GGC	ATC	AAA	AAC	774
Ala	Val	Tyr	Cys	Lys	Phe	His	Tyr	Lys	Thr	Asp	Gln	Gly	Ile	Lys	Asn	
	230					235					240					
CTT	TCT	GTT	GAA	GAT	GCA	GCA	AGA	CTT	GCC	CAC	GAA	GAT	CCT	GAC	TAT	822
Leu	Ser	Val	Glu	Asp	Ala	Ala	Arg	Leu	Ala	His	Glu	Asp	Pro	Asp	Tyr	
245					250					255					260	
GGC	CTC	CGC	GAT	CTT	TTC	AAT	GCC	ATT	GCC	ACA	GGC	AAC	TAC	CCC	TCC	870
Gly	Leu	Arg	Asp	Leu	Phe	Asn	Ala	Ile	Ala	Thr	Gly	Asn	Tyr	Pro	Ser	
			265						270					275		
TGG	ACT	TTA	TAC	ATC	CAG	GTC	ATG	ACA	TTT	AGT	GAG	GCA	GAA	ATT	TTT	918
Trp	Thr	Leu	Tyr	Ile	Gln	Val	Met	Thr	Phe	Ser	Glu	Ala	Glu	Ile	Phe	
			280					285					290			
CCA	TTT	AAT	CCA	TTT	GAT	CTT	ACC	AAG	GTT	TGG	CCT	CAC	GGC	GAC	TAT	966
Pro	Phe	Asn	Pro	Phe	Asp	Leu	Thr	Lys	Val	Trp	Pro	His	Gly	Asp	Tyr	
		295				300						305				
CCT	CTT	ATT	CCA	GTT	GGT	AAA	TTG	GTC	TTA	AAC	CGG	AAC	CCA	GTT	AAT	1014
Pro	Leu	Ile	Pro	Val	Gly	Lys	Leu	Val	Leu	Asn	Arg	Asn	Pro	Val	Asn	
	310					315					320					
TAC	TTT	GCT	GAG	GTT	GAA	CAG	TTG	GCT	TTT	GAC	CCA	AGC	AAC	ATG	CCG	1062
Tyr	Phe	Ala	Glu	Val	Glu	Gln	Leu	Ala	Phe	Asp	Pro	Ser	Asn	Met	Pro	
325					330					335					340	
CCC	GGC	ATC	GAG	CCC	AGC	CCT	GAC	AAA	ATG	CTC	CAG	GGC	CGC	CTT	TTT	1110
Pro	Gly	Ile	Glu	Pro	Ser	Pro	Asp	Lys	Met	Leu	Gln	Gly	Arg	Leu	Phe	
				345					350					355		
GCC	TAT	CCT	GAC	ACT	CAC	CGC	CAC	CGC	CTG	GGA	CCC	AAC	TAT	CTC	CAG	1158
Ala	Tyr	Pro	Asp	Thr	His	Arg	His	Arg	Leu	Gly	Pro	Asn	Tyr	Leu	Gln	
			360					365					370			
ATA	CCT	GTG	AAC	TGT	CCC	TAC	CGT	GCT	CGA	GTG	GCC	AAC	TAC	CAG	CGT	1206
Ile	Pro	Val	Asn	Cys	Pro	Tyr	Arg	Ala	Arg	Val	Ala	Asn	Tyr	Gln	Arg	
		375					380					385				
GAC	GGC	CCC	ATG	TGC	ATG	ATG	GAC	AAT	CAG	GGT	GGG	GCT	CCA	AAT	TAC	1254
Asp	Gly	Pro	Met	Cys	Met	Met	Asp	Asn	Gln	Gly	Gly	Ala	Pro	Asn	Tyr	
	390					395					400					
TAC	CCC	AAT	AGC	TTT	AGT	GCT	CCC	GAG	CAT	CAG	CCT	TCT	GCC	CTG	GAA	1302
Tyr	Pro	Asn	Ser	Phe	Ser	Ala	Pro	Glu	His	Gln	Pro	Ser	Ala	Leu	Glu	
405					410					415				420		
CAC	AGG	ACC	CAC	TTC	TCT	GGG	GAT	GTA	CAG	CGC	TTC	AAC	AGT	GCC	AAC	1350
His	Arg	Thr	His	Phe	Ser	Gly	Asp	Val	Gln	Arg	Phe	Asn	Ser	Ala	Asn	
				425					430					435		

- 27 -

GAT GAC AAT GTC ACT CAG GTG CGG ACT TTC TAT TTG AAA GTG CTG AAT	1398
Asp Asp Asn Val Thr Gln Val Arg Thr Phe Tyr Leu Lys Val Leu Asn	
440 445 450	
GAG GAG CAG AGG AAA CGC CTG TGT GAG AAC ATT GCG GGC CAT CTG AAA	1446
Glu Glu Gln Arg Lys Arg Leu Cys Glu Asn Ile Ala Gly His Leu Lys	
455 460 465	
GAC GCA CAG CTT TTT ATC CAG AAG AAA GCG GTT AAG AAC TTC AGC GAT	1494
Asp Ala Gln Leu Phe Ile Gln Lys Lys Ala Val Lys Asn Phe Ser Asp	
470 475 480	
GTC CAT CCT GAA TAT GGC TCC CGC ATC CAG GCT CTT TTG GAC AAA TAC	1542
Val His Pro Glu Tyr Gly Ser Arg Ile Gln Ala Leu Leu Asp Lys Tyr	
485 490 495 500	
AAT GAG GAG AAA CCT AAG AAC GCA GTT CAC ACC TAT GTG CAG CAT GGG	1590
Asn Glu Glu Lys Pro Lys Asn Ala Val His Thr Tyr Val Gln His Gly	
505 510 515	
TCT CAC TTG TCT GCA AGG GAG AAA GCT AAT CTC TGAGGGTCGG GGGCCTGGCC	1643
Ser His Leu Ser Ala Arg Glu Lys Ala Asn Leu	
520 525	
CTGCACCACG TTGCCGTCCG CTTGTGAAGC AGAGCATGGT GTTCACACCT GTACCCACGG	1703
ATCGCTGGAT GGAAGATTCT CCTGCACTAG ACATGCAAT GCAAGTTTGT GTCTGTAAAA	1763
TGATAATCCA GATTTCTATA GCAAATGATG TAATAATGGC TTTTAATCCT ACTTTCCTGT	1823
GGGTGAATGA AGGTTAAGGC TTAACAATCA TTTAAAAGAA ACATGTATTT GCTTTTGACA	1883
GCTGATTATT CACTTAAAT GACTAGAATG AAAGTTTCTA GCAGAAATAT GATTTTATTT	1943
GACCAGAAAA AGTCTTAGTG ACATTTATGT TTACATATCA TCTCATGACC TATTTTAA	2003
AAATATCACT GTAATTATAT AAGAAGAAAA GATAAAGATA ATTTACTGAG AAATTTAAAT	2063
TTTTCTCAGT TCCCATGAGG AAGAACACAT TGCTGTCTTT TGAAAATAAC TTCAGCACCA	2123
TCATGGCTTG ATGTTTATTC CTGCTTTGAA TTAATCAGGT TTTTAAAC TTGCAATTAC	2183
ATTTATCCTA ATACAGCACT GATTTTGCAG TAGACTGATT TGTAATTGCT TTCCTTTTTC	2243
CAATAAAATA ATCTGTAAAT AAAAAAAAAA AAAAAAAAAA	2282

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 527 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Ala	Asp	Asn	Arg	Asp	Pro	Ala	Ser	Asp	Gln	Met	Lys	His	Trp	Lys
1				5				10						15	
Glu	Gln	Arg	Ala	Ala	Gln	Lys	Pro	Asp	Val	Leu	Thr	Thr	Gly	Gly	Gly
		20					25						30		
Asn	Pro	Val	Gly	Asp	Lys	Leu	Asn	Ser	Leu	Thr	Val	Gly	Pro	Arg	Gly
		35				40					45				
Pro	Leu	Leu	Val	Gln	Asp	Val	Val	Phe	Thr	Asp	Glu	Met	Ala	His	Phe
50						55					60				

Asp Arg Glu Arg Ile Pro Glu Arg Val Val His Ala Lys Gly Ala Gly
 65 70 75 80
 Ala Phe Gly Tyr Phe Glu Val Thr His Asp Ile Thr Arg Tyr Ser Lys
 85 90 95
 Ala Lys Val Phe Glu His Ile Gly Lys Arg Thr Pro Ile Ala Val Arg
 100 105 110
 Phe Ser Thr Val Ala Gly Glu Ser Gly Ser Ala Asp Thr Val Arg Asp
 115 120 125
 Pro Arg Gly Phe Ala Val Lys Phe Tyr Thr Glu Asp Gly Asn Trp Asp
 130 135 140
 Leu Val Gly Asn Asn Thr Pro Ile Phe Phe Ile Arg Asp Ala Leu Leu
 145 150 155 160
 Phe Pro Ser Phe Ile His Ser Gln Lys Arg Asn Pro Gln Thr His Leu
 165 170 175
 Lys Asp Pro Asp Met Val Trp Asp Phe Trp Ser Leu Arg Pro Glu Ser
 180 185 190
 Leu His Gln Val Ser Phe Leu Phe Ser Asp Arg Gly Ile Pro Asp Gly
 195 200 205
 His Arg His Met Asn Gly Tyr Gly Ser His Thr Phe Lys Leu Val Asn
 210 215 220
 Ala Asn Gly Glu Ala Val Tyr Cys Lys Phe His Tyr Lys Thr Asp Gln
 225 230 235 240
 Gly Ile Lys Asn Leu Ser Val Glu Asp Ala Ala Arg Leu Ala His Glu
 245 250 255
 Asp Pro Asp Tyr Gly Leu Arg Asp Leu Phe Asn Ala Ile Ala Thr Gly
 260 265 270
 Asn Tyr Pro Ser Trp Thr Leu Tyr Ile Gln Val Met Thr Phe Ser Glu
 275 280 285
 Ala Glu Ile Phe Pro Phe Asn Pro Phe Asp Leu Thr Lys Val Trp Pro
 290 295 300
 His Gly Asp Tyr Pro Leu Ile Pro Val Gly Lys Leu Val Leu Asn Arg
 305 310 315 320
 Asn Pro Val Asn Tyr Phe Ala Glu Val Glu Gln Leu Ala Phe Asp Pro
 325 330 335
 Ser Asn Met Pro Pro Gly Ile Glu Pro Ser Pro Asp Lys Met Leu Gln
 340 345 350
 Gly Arg Leu Phe Ala Tyr Pro Asp Thr His Arg His Arg Leu Gly Pro
 355 360 365
 Asn Tyr Leu Gln Ile Pro Val Asn Cys Pro Tyr Arg Ala Arg Val Ala
 370 375 380
 Asn Tyr Gln Arg Asp Gly Pro Met Cys Met Met Asp Asn Gln Gly Gly
 385 390 395 400
 Ala Pro Asn Tyr Tyr Pro Asn Ser Phe Ser Ala Pro Glu His Gln Pro
 405 410 415
 Ser Ala Leu Glu His Arg Thr His Phe Ser Gly Asp Val Gln Arg Phe
 420 425 430
 Asn Ser Ala Asn Asp Asp Asn Val Thr Gln Val Arg Thr Phe Tyr Leu
 435 440 445
 Lys Val Leu Asn Glu Glu Gln Arg Lys Arg Leu Cys Glu Asn Ile Ala
 450 455 460
 Gly His Leu Lys Asp Ala Gln Leu Phe Ile Gln Lys Lys Ala Val Lys
 465 470 475 480
 Asn Phe Ser Asp Val His Pro Glu Tyr Gly Ser Arg Ile Gln Ala Leu
 485 490 495
 Leu Asp Lys Tyr Asn Glu Glu Lys Pro Lys Asn Ala Val His Thr Tyr
 500 505 510
 Val Gln His Gly Ser His Leu Ser Ala Arg Glu Lys Ala Asn Leu
 515 520 525

WHAT IS CLAIMED IS:

1. A method of stabilizing spermatozoa membrane and improving spermatozoa survival during migration in oviduct and/or uterus for artificial insemination; which comprises coating spermatozoa with a catalase enzyme.
2. The method of claim 1, wherein the catalase enzyme is isolated from a biological source or is recombinantly produced.
3. The method of claim 1, wherein the catalase enzyme is isolated from oviduct of human, bovine, caprine, equine, ovine or porcine origin.
4. The method of claim 1, wherein the spermatozoa is of bovine, caprine, equine, ovine, porcine, canine, feline, primate, pachyderm or human origin.
5. A composition of spermatozoa for artificial insemination with stabilized spermatozoa membrane and improved spermatozoa survival during migration in oviduct and/or uterus, which comprises spermatozoa coated with a catalase enzyme
6. The composition of claim 5, which further comprises an agent preventing lipid peroxidation.
7. The composition of claim 5, wherein said coated spermatozoa may be frozen.
8. The composition of claim 5, wherein the catalase enzyme is isolated from oviduct of human, bovine, caprine, equine, ovine or porcine origin.

9. The composition of claim 6, wherein the agent preventing lipid peroxidation is selected from the group consisting of Vitamin E (α -tocopherol), Vitamin C (ascorbic acid), pyruvate, glutathion, uric acid, taurine, albumine, DMSO, superoxid dismutase (SOD), catalase and lactoferrin.

10. The composition of claim 5, wherein the spermatozoa is of bovine, caprine, equine, ovine, porcine, canine, feline, primate, pachyderm or human origin.

11. A method of diagnostic of low fertility or infertility in a male subject; which comprises the steps of:

- a) incubating spermatozoa obtained from said male subject with a catalase enzyme or with biological fluid containing a catalase enzyme; and
- b) determining the presence of catalase on spermatozoa membrane; whereby the incapacity of spermatozoa to bind to catalase is indicative of infertility of the subject.

12. The method of claim 11, wherein the subject is of bovine, caprine, equine, ovine, porcine, canine, feline, primate, pachyderm or human origin.

13. The method of claim 11, wherein the determining of step b) is effected using an anti-catalase antibody directly or indirectly detected.

14. A method of diagnostic of low fertility or infertility in a female subject; which comprises the step of determining the absence or presence of an oviductal catalase in oviductal fluid and/or cervical mucus obtained from said subject; whereby the absence

of catalase is indicative of infertility of the subject.

15. The method of claim 14, wherein the subject is of bovine, caprine, equine, ovine, porcine, canine, feline, primate, pachyderm or human origin.



16. The method of claim 14, wherein determining the catalase is effected using an anti-catalase antibody directly or indirectly detected.

17. The use of a catalase enzyme for improving spermatozoa survival during migration in oviduct and/or uterus in cases of female infertility due to the absence of endogenous catalase in the genital tract of the female subject; which comprises administering a catalase enzyme in the female genital tract before coït or coating spermatozoa with a catalase enzyme for artificial insemination.

18. The use of claim 17, wherein the female subject is of bovine, caprine, equine, ovine, porcine, canine, feline, primate, pachyderm or human origin.

19. An oviductal catalase having a molecular weight of about 60 KDa and which binds to a spermatozoa membrane outer surface, wherein said catalase once bound to the spermatozoa membrane outer surface protects said spermatozoa against oxidation.

20. The oviductal catalase of claim 19, wherein said catalase is encoded by a DNA sequence as set forth in SEQ ID NO:1 and/or has an amino acid sequence as set forth in SEQ ID NO:2.



2/5




FIG. 3

3/5




FIG. 4A




FIG. 4B

4/5




FIG. 4C




FIG. 4D

5/5




FIG. 5

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA 98/00120

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N9/08 C12Q1/30 A61K38/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 356 259 A (BANBA KIMIO) 26 October 1982 see example 1 ---	1-10
X	SU 880 420 A (ZORIN VLADIMIR M) 15 November 1981 see abstract ---	1-10
X	DE LAMIRANDE E ET AL: **Human* sperm hyperactivation and capacitation as parts of an oxidative process." FREE RADIC BIOL MED, FEB 1993, 14 (2) P157-66, UNITED STATES, XP002066654 see the whole document --- -/-	1-10

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

17 June 1998

Date of mailing of the international search report

20.07.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx 31 651 eoo nl.
Fax: (+31-70) 340-3016

Authorized officer

Hillenbrand, G

INTERNATIONAL SEARCH REPORT

Internal JI Application No

PCT/CA 98/00120

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE LAMIRANDE E ET AL: "Reactive oxygen species and *human* *spermatozoa*. I. Effects on the motility of intact *spermatozoa* and on sperm axonemes." J ANDROL, SEP-OCT 1992, 13 (5) P368-78, UNITED STATES, XP002066655 see figure 5 ---	1-10
X	AITKEN RJ ET AL: "Redox regulation of tyrosine phosphorylation in *human* *spermatozoa* and its role in the control of *human* sperm function." J CELL SCI, MAY 1995, 108 (PT 5) P2017-25, ENGLAND, XP002066656 see figures I,7 ---	1-10
X	MAMMOTO, A. ET AL.: "Reactive oxygen species block sperm-egg fusion via oxidation of sperm sulfhydryl proteins in mice" BIOLOGY OF REPRODUCTION, vol. 55, 1996, pages 1063-1068, XP000001068 see the whole document ---	1-10
X	FURUTA, S. ET AL.: "Complete nucleotide sequence of cDNA and deduced amino acid sequence of rat liver catalase" PROC. NATL. ACAD. SCI. U.S.A., vol. 83, 1986, pages 313-317, XP000000317 see the whole document -----	19

INTERNATIONAL SEARCH REPORT

International application No
PCT/CA 98/00120

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-3 and 17-18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's .
- ☐ No protest accompanied the payment of additional search fees

page 2 of 2

INTERNATIONAL SEARCH REPORT

International Application No. PCT/CA 98/00120

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 11-16 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 1-3 and 17-18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/CA 98/00120

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4356259	A	26-10-1982	JP 56032417 A	01-04-1981
			JP 62042620 B	09-09-1987
			CA 1142094 A	01-03-1983
			DE 3032340 A	26-03-1981
			FR 2464073 A	06-03-1981
			GB 2057247 A,B	01-04-1981
			NL 8004801 A	03-03-1981

SU 880420	A	15-11-1981	NONE	
